Evidence map›Paper›PMID 34795805›Full record

ArticleDisease markers2021

Comprehensive Analysis of the Immune Implication of TEX41 in Skin Cutaneous Melanoma.

Zhi-Yong Chen, Jie-Qing Huang, Yu Zhu, Yong-Song Chen, Xue-Feng Yu

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhi-Yong ChenDepartment of Burns and Plastic, The Fuling Center Hospital of Chongqing City, Fuling, Chongqing, China.
Jie-Qing HuangDepartment of Burns and Plastic, The Fuling Center Hospital of Chongqing City, Fuling, Chongqing, China.
Yu ZhuDepartment of Burns and Plastic, The Fuling Center Hospital of Chongqing City, Fuling, Chongqing, China.
Yong-Song ChenDepartment of Burns and Plastic, The Fuling Center Hospital of Chongqing City, Fuling, Chongqing, China.
Xue-Feng YuDepartment of Burns and Plastic, The Fuling Center Hospital of Chongqing City, Fuling, Chongqing, China.ORCID https://orcid.org/0000-0002-6609-2118
Fuling Center Hospital of Chongqing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancer RNAs (eRNAs), a subclass of noncoding RNAs from enhancers, have been demonstrated to exhibit important regulatory effects on the expressions of various genes. However, the role of eRNAs in skin cutaneous melanoma (SKCM) remained largely unclear. In this study, we aimed to explore the expression and prognostic value of an enhancer RNA TEX41 in SKCM as well as the associations between TEX41 and tumor-infiltrating immune cells (TICs). We observed that TEX41 expression was distinctly increased in SKCM specimens compared with normal skin specimens using GEPIA. Survival assays based on TGCA datasets revealed that patients with low TEX41 expressions displayed a longer overall survival than those with high TEX41 expression. CIBERSORT datasets revealed that TEX41 was related to 8 types of TICs (macrophages M1, T cells regulatory, plasma cells, mast cells resting, T cells CD8, dendritic cells resting, and T cells follicular helper). Three kinds of TICs were negatively related to TEX41 expressions, including macrophages M2, NK cells resting, and macrophages M0. The expressions of TEX41 were involved in five KEGG pathways, including transcriptional misregulation in cancer, SNARE interactions in vesicular transport, mitophagy-animal, melanoma, melanogenesis, and progesterone-mediated oocyte maturation. Overall, TEX41 can be used as a novel biomarker for the prognosis of SKCM patients and is associated with TICs, indicating it as a therapeutic target for SKCM.

Indexed as

Gene Expression Regulation, NeoplasticTumor MicroenvironmentBiomarkers, TumorCase-Control StudiesCD8-Positive T-LymphocytesCutaneous Malignant MelanomaHumansLymphocytes, Tumor-InfiltratingMelanomaPrognosisRNA, Long NoncodingSkin NeoplasmsBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID34795805
PMCPMC8595038
OpenAlexW3212652359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.